MedTrace Logo

Low Dose Naltrexone for the Treatment of Juvenile Primary Fibromyalgia Syndrome

NCT00855972 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-12-11

No results posted yet for this study

Summary

The purpose of this research is to obtain data or information on the safety and effectiveness of low dose naltrexone (LDN) for treating the symptoms of juvenile primary fibromyalgia syndrome. This is a dose finding study to find whether LDN helps the symptoms of juvenile fibromyalgia, and at what dose it does so.

Conditions

  • Fibromyalgia

Interventions

DRUG

Low Dose Naltrexone

Sponsors & Collaborators

Principal Investigators

  • Jarred Younger · Stanford University

  • Sean Mackey · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-12-31
Completion
2011-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00855972 on ClinicalTrials.gov